DLCO declined earliest, falling measurably about 10 years before the defined onset. By five years before onset, DLCO had ...

Dr Nathan discusses the trajectory of IPF management. How do you envision these investigational agents potentially being implemented into future treatment paradigms for idiopathic pulmonary fibrosis ...

Please provide your email address to receive an email when new articles are posted on . An online survey was created to capture the burden of IPF. Patients frequently reported shortness of breath. IPF ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...

The star, best known for hosting children’s game show Cheggers Play Pop, died in his home surrounded by loved ones. His family said the incurable lung condition had “rapidly worsened towards the end ...

HealthDay News — Recommendations for idiopathic pulmonary fibrosis (IPF) treatment have been updated by an international group of respiratory societies. The updated clinical practice guideline was ...

IPF is a rare, progressive and fatal lung disease with a median survival of 2-5 years. 1 Pirfenidone is one of only two drugs approved to treat IPF, and for those patients able to tolerate treatment, ...

FibroGen is focused on developing pamrevlumab, an innovative drug with potential for IPF treatment, which could capture a share of the multi-billion dollar IPF drug market. The PRAISE study showed ...